ENLV — Enlivex Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $23.28m
- -$0.21m
- 22
- 33
- 29
- 17
Annual balance sheet for Enlivex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 6-K |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 35.7 | 84.1 | 50.2 | 27.3 | 23.5 |
| Net Total Receivables | 0 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 38.1 | 86.4 | 52.3 | 33.8 | 26 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.14 | 8.22 | 14.9 | 2.58 | 0.625 |
| Other Long Term Assets | |||||
| Total Assets | 40.4 | 95.1 | 67.6 | 36.8 | 27.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.37 | 4.72 | 6.61 | 6.06 | 3.8 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.87 | 10.1 | 10.8 | 6.75 | 4.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 35.5 | 85 | 56.8 | 30.1 | 23.6 |
| Total Liabilities & Shareholders' Equity | 40.4 | 95.1 | 67.6 | 36.8 | 27.7 |
| Total Common Shares Outstanding |